NORTH AMERICA IN-VITRO FERTILIZATION MARKET FORECAST 2017-2026
KEY FINDINGS
The North America in-vitro fertilization market is forecasted to evolve with a CAGR of 10.00% from 2017 to 2026. The market worth was evaluated to be at $3676 million in 2016, but with the estimated rise in CGAR, the market is expected to hit $9445 million by the end of 2026.
MARKET INSIGHTS
Canada and United States are the primary markets in this region. The United States captured a major share of the North American market in the year 2016. High occurrence of infertility in old age and significant use of contraceptive drugs in the U.S. are some of the factors which are influencing the market demand. The IVF market is mainly segmented on the basis of end-users, procedures, and product. The Canadian in-vitro fertilization market is also growing significantly due to factors like older age in women, the presence of sexually transmitted disease that causes blockage in the fallopian tubes, hormonal imbalance, etc.
COMPETITIVE INSIGHTS
The Baker Company Inc, Halotech DNA, Auxogyn, Esco Micro Pte. Ltd, Ovascience, Thermo Fisher Scientific Inc, Irvine Scientific (Subsidiary of Nippon Mining Holdings), Cook Medical Inc, Ferring Pharmaceuticals, Andrology Solutions, Vitrolife Ab, Genea, Copper Surgical Inc, Ivftech Aps and Merck Serono are some of the competing players in the In-vitro fertilization market.
The North America in-vitro fertilization market is forecasted to evolve with a CAGR of 10.00% from 2017 to 2026. The market worth was evaluated to be at $3676 million in 2016, but with the estimated rise in CGAR, the market is expected to hit $9445 million by the end of 2026.
MARKET INSIGHTS
Canada and United States are the primary markets in this region. The United States captured a major share of the North American market in the year 2016. High occurrence of infertility in old age and significant use of contraceptive drugs in the U.S. are some of the factors which are influencing the market demand. The IVF market is mainly segmented on the basis of end-users, procedures, and product. The Canadian in-vitro fertilization market is also growing significantly due to factors like older age in women, the presence of sexually transmitted disease that causes blockage in the fallopian tubes, hormonal imbalance, etc.
COMPETITIVE INSIGHTS
The Baker Company Inc, Halotech DNA, Auxogyn, Esco Micro Pte. Ltd, Ovascience, Thermo Fisher Scientific Inc, Irvine Scientific (Subsidiary of Nippon Mining Holdings), Cook Medical Inc, Ferring Pharmaceuticals, Andrology Solutions, Vitrolife Ab, Genea, Copper Surgical Inc, Ivftech Aps and Merck Serono are some of the competing players in the In-vitro fertilization market.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. INSURANCE COVERAGE FOR IVF
3.2.2. GROWTH OF MEDICAL TOURISM
4. MARKET DYNAMICS
4.1. MARKET DEFINITION
4.2. DRIVERS
4.2.1. INCREASING RATE OF INFERTILITY ACROSS THE GLOBE
4.2.2. FLEXIBLE GOVERNMENT REGULATIONS FOR FERTILITY TOURISM
4.2.3. IMPROVED SURROGACY LAWS
4.2.4. HIGH SUCCESS RATES OF ADVANCED IN-VITRO FERTILIZATION TREATMENTS
4.3. RESTRAINTS
4.3.1. HIGH COST
4.3.2. COUNTRY WISE REGULATORY ISSUES
4.4. OPPORTUNITIES
4.4.1. INCREASING DEMAND FOR LOW-COST PROCEDURES
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.5. CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO IVF
4.5.2.1. DIET AND SUPPLEMENTS
4.5.2.2. ACUPUNCTURE
4.5.2.3. THERAPY
4.5.2.4. QIGONG
5. MARKET BY PRODUCT AND PROCEDURES
5.1. BY PRODUCT
5.1.1. REAGENTS
5.1.2. EQUIPMENTS
5.2. BY PROCEDURE
5.2.1. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
5.2.2. PREIMPLANTATION GENETIC DIAGNOSIS (PGD)
5.2.3. FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER)
5.2.4. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. KEY ANALYTICS
7.1. PORTER’S 5 FORCE MODEL
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTE PRODUCTS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. BARGAINING POWER OF SUPPLIERS
7.1.5. INTENSITY OF COMPETITIVE RIVALRY
7.2. VALUE CHAIN ANALYSIS
7.2.1. RAW MATERIAL PROCUREMENT
7.2.2. MANUFACTURING
7.2.3. SUPPLY LOGISTICS
7.2.4. DISTRIBUTION CHANNELS
7.2.5. END USERS
7.3. KEY BUYING CRITERIA
7.3.1. TREATMENT OPTIONS
7.3.2. QUALITY OF MEDICAL PROCEDURES
7.3.3. PRICE OF TREATMENTS
7.3.4. SHIFT TOWARDS MEDICAL TOURISM
7.3.5. REIMBURSEMENT
7.4. REGULATORY FRAMEWORK
7.5. INVESTMENT OUTLOOK
7.5.1. COUNTRY OUTLOOK
7.5.2. END-USER OUTLOOK
7.6. VENDOR LANDSCAPE
7.7. OPPORTUNITY MATRIX
8. GEOGRAPHICAL ANALYSIS
8.1. US
8.2. CANADA
9. COMPETITIVE LANDSCAPE
9.1. MARKET SHARE ANALYSIS
9.1.1. VITROLIFE
9.1.2. COOPER SURGICAL
9.1.3. MERCK
9.1.4. COOK MEDICAL
9.1.5. FERRING PHARMACEUTICALS
9.2. TOP WINNING STRATEGIES
9.3. COMPANY PROFILES
9.3.1. ANDROLOGY SOLUTIONS
9.3.1.1. OVERVIEW
9.3.1.2. PRODUCT PORTFOLIO
9.3.1.3. SCOT ANALYSIS
9.3.1.4. STRATEGIC ANALYSIS
9.3.2. AUXOGYN
9.3.2.1. OVERVIEW
9.3.2.2. PRODUCTS
9.3.2.3. STRATEGIC INITIATIVES
9.3.2.4. SCOT ANALYSIS
9.3.2.5. STRATEGIC ANALYSIS
9.3.3. COOK MEDICAL INC
9.3.3.1. OVERVIEW
9.3.3.2. PRODUCT PORTFOLIO
9.3.3.3. STRATEGIC INITIATIVES
9.3.3.4. SCOT ANALY
9.3.3.5. STRATEGIC ANALYSIS
9.3.4. COPPER SURGICAL INC
9.3.4.1. OVERVIEW
9.3.4.2. PRODUCT PORTFOLIO
9.3.4.3. STRATEGIC INITIATIVES
9.3.4.4. SCOT ANALYSIS
9.3.4.5. STRATEGIC ANALYSIS
9.3.5. ESCO MICRO PTE. LTD.
9.3.5.1. OVERVIEW
9.3.5.2. PRODUCT PORTFOLIO
9.3.5.3. STRATEGIC INITIATIVES
9.3.5.4. SCOT ANALYSIS
9.3.5.5. STRATEGIC ANALYSIS
9.3.6. FERRING PHARMACEUTICALS
9.3.6.1. OVERVIEW
9.3.6.2. PRODUCT PORTFOLIO
9.3.6.3. STRATEGIC INITIATIVES
9.3.6.4. SCOT ANALYSIS
9.3.6.5. STRATEGIC ANALYSIS
9.3.7. GENEA
9.3.7.1. OVERVIEW
9.3.7.2. PRODUCT PORTFOLIO
9.3.7.3. STRATEGIC INITIATIVES
9.3.7.4. SCOT ANALYSIS
9.3.7.5. STRATEGIC ANALYSIS
9.3.8. HALOTECH DNA
9.3.8.1. OVERVIEW
9.3.8.2. PRODUCT PORTFOLIO
9.3.8.3. SCOT ANALYSIS
9.3.8.4. STRATEGIC ANALYSIS
9.3.9. IRVINE SCIENTIFIC (SUBSIDIARY OF NIPPON MINING HOLDINGS)
9.3.9.1. OVERVIEW
9.3.9.2. PRODUCT PORTFOLIO
9.3.9.3. STRATEGIC INITIATIVES
9.3.9.4. SCOT ANALYSIS
9.3.9.5. STRATEGIC ANALYSIS
9.3.10. IVFTECH APS
9.3.10.1. OVERVIEW
9.3.10.2. PRODUCT PORTFOLIO
9.3.10.3. SCOT ANALYSIS
9.3.10.4. STRATEGIC ANALYSIS
9.3.11. MERCK SERONO
9.3.11.1. OVERVIEW
9.3.11.2. PRODUCT PORTFOLIO
9.3.11.3. STRATEGIC INITIATIVES
9.3.11.4. SCOT ANALYSIS
9.3.11.5. STRATEGIC ANALYSIS
9.3.12. OVASCIENCE
9.3.12.1. OVERVIEW
9.3.12.2. PRODUCT PORTFOLIO
9.3.12.3. STRATEGIC INITIATIVES
9.3.12.4. SCOT ANALYSIS
9.3.12.5. STRATEGIC ANALYSIS
9.3.13. THE BAKER COMPANY, INC.
9.3.13.1. OVERVIEW
9.3.13.2. PRODUCT PORTFOLIO
9.3.13.3. SCOT ANALYSIS
9.3.13.4. STRATEGIC ANALYSIS
9.3.14. THERMO FISHER SCIENTIFIC INC
9.3.14.1. OVERVIEW
9.3.14.2. PRODUCT PORTFOLIO
9.3.14.3. STRATEGIC INITIATIVE
9.3.14.4. SCOT ANALYSIS
9.3.14.5. STRATEGIC ANALYSIS
9.3.15. VITROLIFE AB
9.3.15.1. OVERVIEW
9.3.15.2. PRODUCT PORTFOLIO
9.3.15.3. STRATEGIC INITIATIVES
9.3.15.4. SCOT ANALYSIS
9.3.15.5. STRATEGIC ANALYSIS
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM-UP APPROACH
2.4. DATA TRIANGULATION
2.5. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET SUMMARY
3.2. KEY FINDINGS
3.2.1. INSURANCE COVERAGE FOR IVF
3.2.2. GROWTH OF MEDICAL TOURISM
4. MARKET DYNAMICS
4.1. MARKET DEFINITION
4.2. DRIVERS
4.2.1. INCREASING RATE OF INFERTILITY ACROSS THE GLOBE
4.2.2. FLEXIBLE GOVERNMENT REGULATIONS FOR FERTILITY TOURISM
4.2.3. IMPROVED SURROGACY LAWS
4.2.4. HIGH SUCCESS RATES OF ADVANCED IN-VITRO FERTILIZATION TREATMENTS
4.3. RESTRAINTS
4.3.1. HIGH COST
4.3.2. COUNTRY WISE REGULATORY ISSUES
4.4. OPPORTUNITIES
4.4.1. INCREASING DEMAND FOR LOW-COST PROCEDURES
4.4.2. IVF ATTRACTING INVESTMENTS FROM PRIVATE EQUITY INVESTORS
4.5. CHALLENGES
4.5.1. INFERTILITY CONSIDERED A SOCIAL TABOO AMONGST MEN
4.5.2. TRADITIONAL TREATMENTS USED WIDELY AS AN ALTERNATIVE TO IVF
4.5.2.1. DIET AND SUPPLEMENTS
4.5.2.2. ACUPUNCTURE
4.5.2.3. THERAPY
4.5.2.4. QIGONG
5. MARKET BY PRODUCT AND PROCEDURES
5.1. BY PRODUCT
5.1.1. REAGENTS
5.1.2. EQUIPMENTS
5.2. BY PROCEDURE
5.2.1. INTRACYTOPLASMIC SPERM INJECTION (ICSI)
5.2.2. PREIMPLANTATION GENETIC DIAGNOSIS (PGD)
5.2.3. FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER)
5.2.4. OTHERS
6. MARKET BY END-USER
6.1. FERTILITY AND SURGICAL CENTERS
6.2. HOSPITALS AND RESEARCH LABORATORIES
6.3. CRYOBANKS
7. KEY ANALYTICS
7.1. PORTER’S 5 FORCE MODEL
7.1.1. THREAT OF NEW ENTRANTS
7.1.2. THREAT OF SUBSTITUTE PRODUCTS
7.1.3. BARGAINING POWER OF BUYERS
7.1.4. BARGAINING POWER OF SUPPLIERS
7.1.5. INTENSITY OF COMPETITIVE RIVALRY
7.2. VALUE CHAIN ANALYSIS
7.2.1. RAW MATERIAL PROCUREMENT
7.2.2. MANUFACTURING
7.2.3. SUPPLY LOGISTICS
7.2.4. DISTRIBUTION CHANNELS
7.2.5. END USERS
7.3. KEY BUYING CRITERIA
7.3.1. TREATMENT OPTIONS
7.3.2. QUALITY OF MEDICAL PROCEDURES
7.3.3. PRICE OF TREATMENTS
7.3.4. SHIFT TOWARDS MEDICAL TOURISM
7.3.5. REIMBURSEMENT
7.4. REGULATORY FRAMEWORK
7.5. INVESTMENT OUTLOOK
7.5.1. COUNTRY OUTLOOK
7.5.2. END-USER OUTLOOK
7.6. VENDOR LANDSCAPE
7.7. OPPORTUNITY MATRIX
8. GEOGRAPHICAL ANALYSIS
8.1. US
8.2. CANADA
9. COMPETITIVE LANDSCAPE
9.1. MARKET SHARE ANALYSIS
9.1.1. VITROLIFE
9.1.2. COOPER SURGICAL
9.1.3. MERCK
9.1.4. COOK MEDICAL
9.1.5. FERRING PHARMACEUTICALS
9.2. TOP WINNING STRATEGIES
9.3. COMPANY PROFILES
9.3.1. ANDROLOGY SOLUTIONS
9.3.1.1. OVERVIEW
9.3.1.2. PRODUCT PORTFOLIO
9.3.1.3. SCOT ANALYSIS
9.3.1.4. STRATEGIC ANALYSIS
9.3.2. AUXOGYN
9.3.2.1. OVERVIEW
9.3.2.2. PRODUCTS
9.3.2.3. STRATEGIC INITIATIVES
9.3.2.4. SCOT ANALYSIS
9.3.2.5. STRATEGIC ANALYSIS
9.3.3. COOK MEDICAL INC
9.3.3.1. OVERVIEW
9.3.3.2. PRODUCT PORTFOLIO
9.3.3.3. STRATEGIC INITIATIVES
9.3.3.4. SCOT ANALY
9.3.3.5. STRATEGIC ANALYSIS
9.3.4. COPPER SURGICAL INC
9.3.4.1. OVERVIEW
9.3.4.2. PRODUCT PORTFOLIO
9.3.4.3. STRATEGIC INITIATIVES
9.3.4.4. SCOT ANALYSIS
9.3.4.5. STRATEGIC ANALYSIS
9.3.5. ESCO MICRO PTE. LTD.
9.3.5.1. OVERVIEW
9.3.5.2. PRODUCT PORTFOLIO
9.3.5.3. STRATEGIC INITIATIVES
9.3.5.4. SCOT ANALYSIS
9.3.5.5. STRATEGIC ANALYSIS
9.3.6. FERRING PHARMACEUTICALS
9.3.6.1. OVERVIEW
9.3.6.2. PRODUCT PORTFOLIO
9.3.6.3. STRATEGIC INITIATIVES
9.3.6.4. SCOT ANALYSIS
9.3.6.5. STRATEGIC ANALYSIS
9.3.7. GENEA
9.3.7.1. OVERVIEW
9.3.7.2. PRODUCT PORTFOLIO
9.3.7.3. STRATEGIC INITIATIVES
9.3.7.4. SCOT ANALYSIS
9.3.7.5. STRATEGIC ANALYSIS
9.3.8. HALOTECH DNA
9.3.8.1. OVERVIEW
9.3.8.2. PRODUCT PORTFOLIO
9.3.8.3. SCOT ANALYSIS
9.3.8.4. STRATEGIC ANALYSIS
9.3.9. IRVINE SCIENTIFIC (SUBSIDIARY OF NIPPON MINING HOLDINGS)
9.3.9.1. OVERVIEW
9.3.9.2. PRODUCT PORTFOLIO
9.3.9.3. STRATEGIC INITIATIVES
9.3.9.4. SCOT ANALYSIS
9.3.9.5. STRATEGIC ANALYSIS
9.3.10. IVFTECH APS
9.3.10.1. OVERVIEW
9.3.10.2. PRODUCT PORTFOLIO
9.3.10.3. SCOT ANALYSIS
9.3.10.4. STRATEGIC ANALYSIS
9.3.11. MERCK SERONO
9.3.11.1. OVERVIEW
9.3.11.2. PRODUCT PORTFOLIO
9.3.11.3. STRATEGIC INITIATIVES
9.3.11.4. SCOT ANALYSIS
9.3.11.5. STRATEGIC ANALYSIS
9.3.12. OVASCIENCE
9.3.12.1. OVERVIEW
9.3.12.2. PRODUCT PORTFOLIO
9.3.12.3. STRATEGIC INITIATIVES
9.3.12.4. SCOT ANALYSIS
9.3.12.5. STRATEGIC ANALYSIS
9.3.13. THE BAKER COMPANY, INC.
9.3.13.1. OVERVIEW
9.3.13.2. PRODUCT PORTFOLIO
9.3.13.3. SCOT ANALYSIS
9.3.13.4. STRATEGIC ANALYSIS
9.3.14. THERMO FISHER SCIENTIFIC INC
9.3.14.1. OVERVIEW
9.3.14.2. PRODUCT PORTFOLIO
9.3.14.3. STRATEGIC INITIATIVE
9.3.14.4. SCOT ANALYSIS
9.3.14.5. STRATEGIC ANALYSIS
9.3.15. VITROLIFE AB
9.3.15.1. OVERVIEW
9.3.15.2. PRODUCT PORTFOLIO
9.3.15.3. STRATEGIC INITIATIVES
9.3.15.4. SCOT ANALYSIS
9.3.15.5. STRATEGIC ANALYSIS
LIST OF TABLES
Table 1 NORTH AMERICA IN-VITRO FERTILIZATION MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 2 NORTH AMERICA IVF MARKET BY PRODUCT AND PROCEDURES 2017-2026 ($ MILLION)
Table 3 NORTH AMERICA IVF MARKET BY PRODUCTS 2017-2026 ($ MILLION)
Table 4 NORTH AMERICA IVF MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Table 5 NORTH AMERICA IVF MARKET BY END-USER 2017-2026 ($ MILLION)
Table 6 NORTH AMERICA IVF MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 1 NORTH AMERICA IN-VITRO FERTILIZATION MARKET BY COUNTRY 2017-2026 ($ MILLION)
Table 2 NORTH AMERICA IVF MARKET BY PRODUCT AND PROCEDURES 2017-2026 ($ MILLION)
Table 3 NORTH AMERICA IVF MARKET BY PRODUCTS 2017-2026 ($ MILLION)
Table 4 NORTH AMERICA IVF MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Table 5 NORTH AMERICA IVF MARKET BY END-USER 2017-2026 ($ MILLION)
Table 6 NORTH AMERICA IVF MARKET BY COUNTRY 2017-2026 ($ MILLION)
LIST OF FIGURES
Figure 1 NORTH AMERICA IN-VITRO FERTILIZATION MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Figure 2 EVOLUTION OF IVF MARKET
Figure 3 FALLING BIRTH RATE IN THE US (1960-2015)
Figure 4 NORTH AMERICA REAGENTS MARKET 2017-2026 ($ MILLION)
Figure 5 NORTH AMERICA EQUIPMENTS MARKET 2017-2026 ($ MILLION)
Figure 6 NORTH AMERICA INTRACYTOPLASMIC SPERM INJECTION (ICSI) MARKET 2017-2026 ($ MILLION)
Figure 7 NORTH AMERICA PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET 2017-2026 ($ MILLION)
Figure 8 NORTH AMERICA FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER) MARKET 2017-2026 ($ MILLION)
Figure 9 NORTH AMERICA OTHERS MARKET 2017-2026 ($ MILLION)
Figure 10 NORTH AMERICA FERTILITY AND SURGICAL CENTERS MARKET 2017-2026 ($ MILLION)
Figure 11 NORTH AMERICA HOSPITALS AND RESEARCH LABORATORIES MARKET 2017-2026 ($ MILLION)
Figure 12 NORTH AMERICA CRYOBANKS MARKET 2017-2026 ($ MILLION)
Figure 13 INVESTMENT PROPOSITION FOR NORTH AMERICA IVF MARKET BY COUNTRY – 2016
Figure 14 INVESTMENT PROPOSITION FOR NORTH AMERICA IVF MARKET BY END-USER - 2016
Figure 15 CONTRACEPTIVE PREVALENCE AND UNMET NEED FOR FAMILY PLANNING AMONG MARRIED OR IN-UNION WOMEN AGED 15 TO 49 YEARS IN NORTH AMERICA IN (%) 2015
Figure 16 NUMBER OF IVF CYCLES PERFORMED IN THE US
Figure 17 UNITED STATES IVF MARKET 2017-2026 ($ MILLION)
Figure 18 FERTILITY RATE IN CANADA (NO. OF CHILD PER WOMEN)
Figure 19 CANADA IVF MARKET 2017-2026 ($ MILLION)
Figure 20 NORTH AMERICA IVF MARKET SHARE OF MAJOR COMPANIES – 2016
Figure 1 NORTH AMERICA IN-VITRO FERTILIZATION MARKET BY PROCEDURE 2017-2026 ($ MILLION)
Figure 2 EVOLUTION OF IVF MARKET
Figure 3 FALLING BIRTH RATE IN THE US (1960-2015)
Figure 4 NORTH AMERICA REAGENTS MARKET 2017-2026 ($ MILLION)
Figure 5 NORTH AMERICA EQUIPMENTS MARKET 2017-2026 ($ MILLION)
Figure 6 NORTH AMERICA INTRACYTOPLASMIC SPERM INJECTION (ICSI) MARKET 2017-2026 ($ MILLION)
Figure 7 NORTH AMERICA PRE-IMPLANTATION GENETIC DIAGNOSIS (PGD) MARKET 2017-2026 ($ MILLION)
Figure 8 NORTH AMERICA FROZEN EMBRYO TRANSFER/REPLACEMENT (FET/FER) MARKET 2017-2026 ($ MILLION)
Figure 9 NORTH AMERICA OTHERS MARKET 2017-2026 ($ MILLION)
Figure 10 NORTH AMERICA FERTILITY AND SURGICAL CENTERS MARKET 2017-2026 ($ MILLION)
Figure 11 NORTH AMERICA HOSPITALS AND RESEARCH LABORATORIES MARKET 2017-2026 ($ MILLION)
Figure 12 NORTH AMERICA CRYOBANKS MARKET 2017-2026 ($ MILLION)
Figure 13 INVESTMENT PROPOSITION FOR NORTH AMERICA IVF MARKET BY COUNTRY – 2016
Figure 14 INVESTMENT PROPOSITION FOR NORTH AMERICA IVF MARKET BY END-USER - 2016
Figure 15 CONTRACEPTIVE PREVALENCE AND UNMET NEED FOR FAMILY PLANNING AMONG MARRIED OR IN-UNION WOMEN AGED 15 TO 49 YEARS IN NORTH AMERICA IN (%) 2015
Figure 16 NUMBER OF IVF CYCLES PERFORMED IN THE US
Figure 17 UNITED STATES IVF MARKET 2017-2026 ($ MILLION)
Figure 18 FERTILITY RATE IN CANADA (NO. OF CHILD PER WOMEN)
Figure 19 CANADA IVF MARKET 2017-2026 ($ MILLION)
Figure 20 NORTH AMERICA IVF MARKET SHARE OF MAJOR COMPANIES – 2016
